Published: 2017-01-12

Hyperandrogenism-insulin resistance-acanthosis nigricans syndrome with PCOS and Hashimoto’s thyroiditis: case report

Amarnath Kulkarni, Shashank Kumar Srivastav, Saraswathi Susarla, Usha Kulkarni, C. Ashok Kumar, Sunita Chikkala, Sheik Majeeda Tabassum


Female hyperandrogenism is a frequent motive of consultation. It is revealed by hirsutism, acne or seborrhea, and disorders in menstruation cycle combined or not with virilisation signs. Several etiologies are incriminated but the hyperandrogenism-insulin resistance-acanthosis nigricans syndrome is rare. A 21-year female, having had a three-year-old secondary amenorrhea, known case of hypothyroidism since 4 years on medication. The exam revealed a patient, hypertensive with blood pressure at 170/110 mmHg with a Body Mass Index (BMI) at 40.08 (Obese Class-3, as per WHO 2004) and a waist measurement of 106cm, a severe hirsutism assessed to be 27 according to Ferriman and Gallwey scale, acanthosis nigricans behind the neck and elbows. The assessment carried out revealed testosteronemia at 1.07 ng/mL, which is more than twice the upper normal of the laboratory. Imaging studies revealed enlarged right adrenal gland, hepatomegaly with fatty infiltration of grade-1 also bilateral polycystic ovaries. The retained diagnosis is HAIR-AN syndrome with polycystic ovaries, hypertension, type-II diabetes mellitus, hypothyroidism since last 4-years and dyslipidemia and was provided with metformin 500 mg thrice daily, spironolactone 25 mg twice daily, atorvastatin 20 mg once daily, telmisartan 20 mg once daily with continuation of eltroxin 50 Mcg for hypothyroidism. To our knowledge this is the first case report of HAIR-AN syndrome in 21 year old female associated with Hashimoto’s thyroiditis, dyslipidaemia, hypertension and type-2-diabetes and this case also highlights about early diagnosis and management of HAIR-AN Syndrome with PCOS and Hashimoto’s thyroiditis  which could help prevent long-term sequalae such as cardiovascular disease and endometrial cancer and with the advent of knowledge and availability of health resources we can prevent long-term adverse effects (threefold) on health of women. This woman should be observed for these ailments in later life. 



HAIR-AN syndrome, Polycystic ovary syndrome, Insulin resistance, Type-II diabetes mellitus, Hashimoto’s thyroiditis, Dyslipidaemia

Full Text:



Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med. 2005;353(24):2578-88.

Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, et al. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update. 2012;18(2):146-70.

Chabbert-Buffet N, Droumaguet C, Salenave S, Bry H, Young J. Hirsutisme et hyperandroge ́nie: strate ́gie diagnostique et principes du traitement. Me ́decine Clinique Endocrinologie & Diabe`te. 2011;50:53-60.

Peigne ́ M., Villers-Capelle A, Robin G, Dewailly D. Hyperandroge ́nie fe ́minine. La Presse Me ́dicale. 2013;42(11):1487-99.

Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456-88.

Rager KM, Omar HA. Androgen excess disorders in women: the severe insulin-resistant hyperandrogenic syndrome, HAIR-AN”. Sci World J. 2006;6:116-21.

Polson DW, Adams J, Wadsworth J, Franks S. Polycystic ovaries: a common finding in normal women. Lancet. 1988;1:870-2.

8. Michelmore KF, Balen AH, Dunger DB, Vessey MP. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf). 1999;51:779–86.

Jonard S, Robert Y, Cortet-Rudelli C, Decanter C, Dewailly D. Ultrasound examination of polycystic ovaries: is it worth counting the follicles? Hum Reprod. 2003;18:598-603.

Balen AH, Laven JS, Tan SL, Dewailly D. The ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505-14.

Rajkowha M, Glass MR, Rutherford AJ, Michelmore K, Balen AH. Polycystic ovary syndrome: a risk factor for cardiovascular disease? BJOG. 2000;107:11-8.

Royal College of Obstetricians and Gynaecologists. Long-term consequences of polycystic ovary syndrome. Guideline No. 33. London: RCOG; 2003. Available at: elineID=50.

Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol. 1998;51:581-6.

Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovary syndrome. Hum Reprod. 2001;16:1995-8.

Nakazawa, Donna. Hashimoto’s thyroiditis. In: Nakazawa, Donna, eds. The Autoimmune Epidemic. 4th ed. New York: Simon & Schuster; 2008: 32-35.

Office on Women's Health, U.S. Department of Health and Human Services. Hashimoto’s disease fact sheet, July 16, 2012. Available at: (or Accessed 23 November 2014.

Staecker Hinrich, Thomas R. Van De Water, Van de Water Thomas R. Hashimoto’s thyroiditis. In: Staecker Hinrich, Thomas R. Van De Water, Van de Water Thomas R, eds. Otolaryngology: Basic Science and Clinical Review. 5th ed. Stuttgart: Thieme; 2006: 56.

Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med. 1996;335:99-107.

Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am. 2003;30:337-52.

Pfeifer SLE, Wilson RM, Gawkrodger DJ. Clearance of acanthosis nigricans associated with the HAIR-AN syndrome after partial pancreatectomy. Postgrad Med J. 1999;75:421-3.

Haas DA, Carr BR, Attia GR. Effects of metformin on body mass index, menstrual cyclicity, and ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2003;79:469-81.

Schroeder B, Ding X, Pfaff-Amesse T. From HAIR-AN to eternity. J Pediatr Adolesc Gynecol. 2002;15:235-40.